glp-1 treatment for pre-diabetes Diabetes Patients Also Struggle to Access Agonists GLP-1 Receptor Agonists as Treatments

In Q1 2025, 24% of patients with both diabetes/obesity and OSA initiated a GLP-1 therapy within six months of diagnosis, compared to 18% of patients with diabetes/obesity alone

23 This need for injection can limit patient use and may also restrict the possibility of combining these drugs in fixed-dose treatments with other therapies for cardio-metabolic conditions

Immunocompromised individuals, critically ill patients, those with severe acute pancreatitis, people with central venous catheters, and individuals with short bowel syndrome should avoid probiotics without medical supervision

Genetic Factors Influencing Your Rebound Risk Your personal risk of rebound weight gain may be partly determined by genetic variants affecting appetite and metabolic regulation

Having pre-portioned, protein-forward meals ready in the fridge eliminates the need to rely on appetite or motivation to eat well